GLP-1 FAQ 2026 — Ozempic, Wegovy, Mounjaro & Zepbound Questions

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications originally developed to treat type 2 diabetes. They work by mimicking the GLP-1 hormone, which helps regulate blood sugar levels, slow gastric emptying, and reduce appetite. Common GLP-1 medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

GLP-1 medications promote weight loss by reducing appetite and increasing feelings of fullness after eating. They slow the rate at which food leaves the stomach, helping you feel satisfied with smaller portions. Clinical trials have shown average weight loss of ~15% with Ozempic, ~22% with Mounjaro, and ~20% with Zepbound, depending on dosage and individual factors.

When losing weight rapidly on GLP-1 medications, the body can lose both fat and lean muscle mass. Adequate protein intake helps preserve muscle mass during weight loss, which is critical for maintaining metabolic health and physical function. Most healthcare providers recommend GLP-1 users consume significantly more protein than the standard dietary guidelines suggest.

Most experts recommend GLP-1 users consume 1.2 to 1.6 grams of protein per kilogram of body weight daily (approximately 0.55 to 0.73 grams per pound), though individual needs vary. For example, a person weighing 80 kg should aim for 96-128 grams of protein per day. Use our Protein Calculator for a personalized recommendation based on your specific profile.

In clinical trials, patients taking semaglutide lost an average of ~15% of their body weight over 68 weeks (STEP-1 trial, 2.4mg dose). Individual results vary based on factors such as starting weight, dosage, diet, and exercise habits. Some patients may lose more or less than the average.

Clinical trials showed that patients on Mounjaro (tirzepatide) at the highest dose lost an average of ~22% of their body weight over 72 weeks (SURMOUNT-1 trial). Mounjaro is a dual GIP/GLP-1 receptor agonist, which may contribute to its higher average weight loss compared to GLP-1-only medications. Results vary significantly from person to person.

Without insurance, Ozempic typically costs between $900 and $1,350 per month at retail pharmacies in the United States. Some patients find lower prices through manufacturer savings programs, compounding pharmacies, or international pharmacies. Use our Cost Calculator to compare pricing options for your specific situation.

The most common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are usually mild to moderate and tend to improve over time as the body adjusts to the medication. More serious but rare side effects can include pancreatitis, gallbladder problems, and thyroid tumors. Always discuss potential side effects with your healthcare provider.

Yes, certain GLP-1 medications are FDA-approved specifically for weight management. Wegovy (semaglutide) and Zepbound (tirzepatide) are approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Your doctor can determine if you are a suitable candidate.

GLP-1 medications are generally considered long-term treatments. Most clinical guidelines suggest continuing the medication as long as it remains effective and well-tolerated. Studies have shown that weight regain is common after discontinuation, so many patients stay on these medications indefinitely under medical supervision.

Research indicates that most people regain a significant portion of lost weight within one to two years of stopping GLP-1 medications. Appetite typically returns to pre-treatment levels, and metabolic changes may reverse. This is why many healthcare providers recommend ongoing treatment and why building sustainable diet and exercise habits while on medication is important.

Compounded GLP-1 medications are produced by compounding pharmacies and are not FDA-approved. While they can be significantly cheaper, their safety and efficacy are not guaranteed to the same standard as brand-name medications. If you consider compounded options, ensure the pharmacy is licensed and accredited, and always consult your healthcare provider before switching from a brand-name product.

Both Ozempic and Wegovy contain semaglutide — the same active ingredient. The key differences are: (1) FDA indication: Ozempic is approved for Type 2 diabetes and cardiovascular risk reduction; Wegovy is approved specifically for chronic weight management. (2) Dose: Ozempic's maximum dose is 2.0mg weekly; Wegovy goes up to 2.4mg weekly. (3) Insurance coverage: diabetes plans typically cover Ozempic; obesity-focused plans cover Wegovy. In clinical trials, the 2.4mg Wegovy dose showed ~15.3% average weight loss.

Mounjaro and Zepbound both contain tirzepatide — Eli Lilly's dual GIP/GLP-1 receptor agonist. They use identical dosing (2.5mg–15mg weekly). The difference is FDA indication: Mounjaro is approved for Type 2 diabetes; Zepbound was approved in November 2023 specifically for chronic weight management in adults with obesity. Some insurance plans cover one but not the other. If your goal is weight loss and your insurance covers both, either medication will produce the same clinical result since they are the same molecule.

Ozempic is not FDA-approved for weight management in people without diabetes — that indication belongs to Wegovy. However, doctors can legally prescribe any medication off-label for any clinical reason. Many physicians do prescribe Ozempic off-label for weight loss in non-diabetic patients, particularly when Wegovy is unavailable or not covered by insurance. You should discuss this option with your doctor. If weight management is your primary goal and you don't have diabetes, Wegovy or Zepbound may be the more appropriate starting point.

You may notice reduced appetite and earlier satiety within the first 1–2 weeks of starting a GLP-1 medication, even at the initial low dose. Measurable weight loss on the scale typically begins in weeks 4–8 as the dose escalates toward therapeutic levels. Maximum weight loss effect is generally reached between months 6–12. The first few months are dominated by the titration schedule and adjusting to side effects; significant weight loss results become more apparent in months 3–6.

While no foods are strictly forbidden, several food types tend to worsen GLP-1 side effects: (1) High-fat foods — because GLP-1 medications slow gastric emptying, fatty meals can cause prolonged nausea and discomfort. (2) Highly processed, high-calorie foods — these don't trigger the same satiety response even with reduced appetite. (3) Carbonated beverages — can increase bloating and discomfort. (4) Large meals — eating smaller portions more frequently is generally much better tolerated. Focus on protein-first eating, prioritize nutrient-dense whole foods, and avoid eating past the point of early fullness.

Research consistently shows that weight regain occurs after stopping GLP-1 medications. The STEP-4 trial (Wilding et al., Diabetes, Obesity and Metabolism, 2022) showed that participants who stopped semaglutide regained an average of two-thirds of their lost weight within one year. The SURMOUNT-4 trial showed similar results with tirzepatide. This happens because GLP-1 medications correct an underlying hormonal dysfunction in appetite regulation — they don't permanently change your metabolic set point. This is why most obesity medicine specialists consider these long-term or lifelong treatments, similar to medications for hypertension or diabetes.

Head-to-head trial data (SURPASS-J-Mono) and indirect comparison studies consistently show tirzepatide (Mounjaro/Zepbound) produces greater weight loss than semaglutide (Ozempic/Wegovy). In the SURMOUNT-1 trial, tirzepatide at 15mg produced 22.5% average weight loss vs. 15.3% for semaglutide 2.4mg in STEP-1. A 2023 network meta-analysis confirmed this superiority. However, 'better' depends on your individual situation — Ozempic has more extensive cardiovascular outcome data, may be better covered by your insurance, and some patients respond extremely well to semaglutide while responding less to tirzepatide. Your doctor can help you decide.

All major GLP-1 medications are injected once weekly using a prefilled auto-injector pen. The typical injection day is the same day each week (e.g., every Monday). Dose titration schedules vary by medication: Ozempic starts at 0.25mg for 4 weeks, then increases to 0.5mg, 1.0mg, and 2.0mg in monthly increments. Mounjaro/Zepbound start at 2.5mg and increase by 2.5mg every 4 weeks up to a maximum of 15mg. Injection sites include the abdomen, thigh, or upper arm. Rotate sites each week to prevent skin reactions.

Yes, all GLP-1 medications — including Ozempic, Wegovy, Mounjaro, and Zepbound — require a valid prescription from a licensed healthcare provider in the United States. This includes prescriptions written by telehealth platforms. You cannot legally purchase these medications from legitimate US pharmacies without a prescription. Beware of websites claiming to sell these medications without a prescription, as these sources may provide counterfeit or contaminated products.

Unopened GLP-1 pens must be refrigerated at 36–46°F (2–8°C) until you are ready to use them. Once opened (in-use), most pens can be stored at room temperature (up to 77°F/25°C) for up to 28–56 days depending on the specific medication — check your medication guide for exact timeframes. Never freeze GLP-1 pens; freezing destroys the medication. Keep pens away from direct sunlight and heat. For Ozempic, the pen cap must be kept on when not in use to protect from light.

GLP-1 medications should not be used during pregnancy. Animal studies showed adverse effects on fetal development at doses used in clinical practice. All major GLP-1 medications carry a recommendation to discontinue at least 2 months before a planned pregnancy. Women of childbearing potential should use effective contraception while on these medications. Interestingly, GLP-1 medications may improve fertility in women with PCOS (polycystic ovary syndrome) by reducing insulin resistance and body weight — which can restore regular ovulation. Discuss your fertility plans with your doctor before starting treatment.